Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Update

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) saw a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 6,430,000 shares, a growth of 21.3% from the October 31st total of 5,300,000 shares. Based on an average daily volume of 459,500 shares, the days-to-cover ratio is currently 14.0 days.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on RVPH. EF Hutton Acquisition Co. I upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd. Benchmark reaffirmed a “speculative buy” rating and issued a $17.00 price objective on shares of Reviva Pharmaceuticals in a research note on Monday, August 26th. Finally, Maxim Group reissued a “hold” rating on shares of Reviva Pharmaceuticals in a research note on Friday, August 16th.

Reviva Pharmaceuticals Stock Performance

RVPH stock traded up $0.10 during mid-day trading on Friday, reaching $1.24. The company had a trading volume of 272,917 shares, compared to its average volume of 720,177. The firm has a fifty day simple moving average of $1.20 and a 200 day simple moving average of $1.20. The company has a market capitalization of $41.47 million, a price-to-earnings ratio of -1.12 and a beta of -0.05. Reviva Pharmaceuticals has a fifty-two week low of $0.60 and a fifty-two week high of $5.67.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC lifted its stake in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 278,496 shares of the company’s stock after buying an additional 42,376 shares during the period. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent quarter. 63.18% of the stock is currently owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.